4D Molecular announced the appointment of Uneek Mehra as chief financial and business officer of 4DMT. Mehra will succeed August Moretti, who is retiring, and has agreed to serve in an advisory capacity to support Mehra’s transition. Mehra will lead 4DMT’s finance, business development, and precommercial functions and will be a member of 4DMT’s executive team, reporting to David Kirn, co-founder and CEO of 4DMT. Mehra most recently worked ar Myovant Sciences.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on FDMT:
- 4DMT Appoints Uneek Mehra as Chief Financial and Business Officer
- 4DMT to Participate in Upcoming Investor Conferences
- 4D Molecular begins enrollment in Phase 2 DME trial, expands Phase 2 AMD trial
- 4D Molecular files $300M mixed securities shelf
- 4D Molecular sees cash, equivalents funding operations into 1H26